Efficacy of Pre-Treatment with Remimazolam on Prevention of Propofol-Induced Injection Pain in Patients Undergoing Gastroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063793

Enrollment

Unknown

Registered

2022-09-16

Start date

2022-09-20

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

propofol-induced injection pain

Interventions

Group 1 :remimazolam

Group 2:normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 140 patients underwent elective gastroscopy under general anesthesia, regardless of gender, ASA grade I-II; age 18-65 years; BMI 18-28 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Patients with recent upper respiratory tract infection and asthma; 2. Those who are allergic to benzodiazepines and propofol; 3. Patients with neurological or mental diseases; 4. Those suspected of abusing narcotic analgesics or sedatives; 5. People with difficulties in respiratory management; 6. Pregnant and lactating women; 7. Men with family planning in the past 3 months.

Design outcomes

Primary

Measure	Time frame
the incidence of propofol-induced injection pain;	—

Secondary

Measure	Time frame
the intensity of propofol-induced injection pain;blood pressure;heart rate;pulse oximetry;satisfaction of people;adverse events;	—

Countries

China

Contacts

Public ContactYuan Ruimei

Jinan Central Hospital; Central Hospital Affiliated to Shandong First Medical University

subave@sina.cn+86 15554127179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026